CD8A and neoplasm: Blood samples taken immediately before tumor challenge (day 0) show a CD62Lhigh phenotype for the majority of OVA- specific CD8+ T cells; this was more prominent in mice vaccinated twice (Figure 5D) compared to mice vaccinated three times (Figure 5C) (***, p < 0.001).